1
/
of
1
Velfa (Sofosbuvir + Velpatasvir)
Velfa (Sofosbuvir + Velpatasvir)
Regular price
₱23,580.00 PHP
Regular price
Sale price
₱23,580.00 PHP
Unit price
₱842.14 each
Taxes included.
Quantity
Couldn't load pickup availability
Velfa is a fixed-dose combination antiviral medication containing sofosbuvir and velpatasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection. This dual-active formulation targets multiple stages of the HCV replication cycle, offering a potent therapeutic approach for patients with genotype 1-6 HCV infections.
Sofosbuvir functions as a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, while velpatasvir acts as a non-structural protein 5A (NS5A) inhibitor. Together, these components work synergistically to suppress viral replication and achieve sustained virologic response (SVR).
Velfa is indicated for use in adult patients with chronic HCV infection, including those with compensated cirrhosis. The medication may be used as monotherapy or in combination with ribavirin, depending on the patient's genotype, treatment history, and baseline resistance-associated variants. Treatment duration typically spans 12 weeks for treatment-naïve and treatment-experienced patients without cirrhosis, with potential adjustments for cirrhotic patients.
Key benefits include high cure rates exceeding 95-99% SVR across HCV genotypes, a well-tolerated safety profile with minimal drug-drug interactions compared to first-generation direct-acting antivirals, and oral once-daily dosing that enhances medication adherence.
Velfa should be administered under medical supervision with appropriate baseline HCV RNA testing and liver function assessments. Contraindications and precautions apply for patients with decompensated cirrhosis or concurrent use with certain medications that induce or inhibit cytochrome P450 pathways.
Available through licensed pharmacy channels in the Philippines for qualifying patients with valid prescriptions.
Sofosbuvir functions as a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, while velpatasvir acts as a non-structural protein 5A (NS5A) inhibitor. Together, these components work synergistically to suppress viral replication and achieve sustained virologic response (SVR).
Velfa is indicated for use in adult patients with chronic HCV infection, including those with compensated cirrhosis. The medication may be used as monotherapy or in combination with ribavirin, depending on the patient's genotype, treatment history, and baseline resistance-associated variants. Treatment duration typically spans 12 weeks for treatment-naïve and treatment-experienced patients without cirrhosis, with potential adjustments for cirrhotic patients.
Key benefits include high cure rates exceeding 95-99% SVR across HCV genotypes, a well-tolerated safety profile with minimal drug-drug interactions compared to first-generation direct-acting antivirals, and oral once-daily dosing that enhances medication adherence.
Velfa should be administered under medical supervision with appropriate baseline HCV RNA testing and liver function assessments. Contraindications and precautions apply for patients with decompensated cirrhosis or concurrent use with certain medications that induce or inhibit cytochrome P450 pathways.
Available through licensed pharmacy channels in the Philippines for qualifying patients with valid prescriptions.
Share
